Table 4.
Bivariate associations between patient characteristics and mortality for the 196 patients in the validation cohort.
| Died during first 30 days N=105 |
Alive N=105 |
p value | ||
|---|---|---|---|---|
| Demographic | Age median [IQR] | 62 [50, 70] | 59 [50, 67] | 0.12 |
| Male n(%) | 61 (58) | 54 (59) | 0.86 | |
| White n(%) | 62 (59) | 57 (63) | 0.34 | |
| Black n(%) | 31 (30) | 29 (32) | ||
| Other race n(%) | 12 (11) | 5 (5.5) | ||
| Hematological Malignancy Variables | Acute Myeloid Leukemia n(%) | 48 (46) | 34 (37) | 0.76 |
| Acute Lymphocytic Leukemia n(%) | 13 (12) | 9 (9.9) | ||
| Non-Hodgkin Lymphoma n(%) | 19 (18) | 22 (24) | ||
| Hodgkin Lymphoma n(%) | 2 (1.9) | 5 (5.5) | ||
| Multiple Myeloma n(%) | 11 (10.5) | 9 (9.9) | ||
| Myelodysplastic Syndrome/Myelofibrosis n(%) | 1 (1.0) | 2 (2.2) | ||
| Chronic Myeloid Leukemia n(%) | 4 (3.8) | 4 (4.4) | ||
| Chronic Lymphocytic Leukemia n(%) | 7 (6.7) | 6 (6.6) | ||
| Months Since Diagnosis | 13 [3.2, 40] | 8.7 [2.0, 24] | 0.19 | |
| Allogenieic SCT n(%) | 40 (38) | 33 (36) | 0.79 | |
| SCT complication n(%) | 17 (58) | 16 (52) | 0.61 | |
| Days since SCT median [IQR] | 77 [31, 217] | 88 [18, 201] | 0.91 | |
| Chemotherapy in previous 2 months n(%) | 79 (75) | 64 (71) | 0.52 | |
| Neutrophils < 500 cells/μL on ICU admission n(%) | 43 (42) | 39 (43) | 0.88 | |
| Poor performance status n(%) | 16 (15) | 11 (12) | 0.52 | |
| Relapsed/Progressive Disease n(%) | 65 (62) | 39 (43) | 0.008 | |
| Other Chronic Diseases | Lung disease n(%) | 14 (13) | 15 (17) | 0.51 |
| Cardiovascular disease n(%) | 26 (25) | 24 (26) | 0.8 | |
| Diabetes n(%) | 25 (24) | 23 (25) | 0.81 | |
| Additional malignancy n(%) | 28 (27) | 20 (22) | 0.45 | |
| Chronic Kidney Disease n(%) | 10 (9.5) | 9 (9.9) | 0.93 | |
| Deep Venous Thrombosis/Pulmonary n(%)Embolus | 10 (9.5) | 12 (13) | 0.42 | |
| Autoimmune n(%) | 7 (6.7) | 5 (5.5) | 0.78 | |
| Liver disease n(%) | 1 (0.95) | 5 (5.5) | 0.1 | |
| Sleep disordered breathing n(%) | 5 (4.8) | 7 (7.7) | 0.55 | |
| ICU Variables | Days from hospital admission to ICU admission median [IQR] | 4 [0, 14] | 1 [0, 10] | 0.02 |
| ICU length of stay median [IQR] | 5 [1, 10] | 4 [2, 9] | 0.77 | |
| Vasoactive agents n(%) | 65 (62) | 39 (43) | 0.01 | |
| Acute renal replacement therapy n(%) | 20 (19) | 9 (9.9) | 0.11 | |
| Invasive mechanical ventilation n(%) | 71 (68) | 26 (29) | <0.001 | |
| Ventilator Days median [IQR] | 1 [0, 5] | 0 [0, 2] | <0.001 | |
| SOFA Score median [IQR] | 9 [7, 13] | 7 [4, 9] | <0.001 | |
| SOFA-HM Score median [IQR] | 10 [8, 15] | 7 [4, 11] | <0.001 | |
| APACHE II Score median [IQR] | 26 [22, 31] | 21 [18, 29] | <0.001 | |